跳至主要内容
临床试验/EUCTR2021-005876-21-DK
EUCTR2021-005876-21-DK进行中(未招募)1 期

The Danish Out-of-Hospital Cardiac Arrest study (DANOHCA) - The DANOHCA study

Department of Cardiology, Copenhagen University Hospital, Rigshospitalet0 个研究点目标入组 1,000 人开始时间: 2021年12月20日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
1,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Age =18 years
  • 2. OHCA of presumed cardiac cause
  • 3. Sustained ROSC#
  • 4. Unconsciousness (GCS <9) (patients not able to obey verbal commands) after sustained ROSC at the time of randomization
  • # Sustained ROSC: Sustained ROSC is when chest compressions or mechanical circulatory support have been not required for 20 consecutive minutes and signs of circulation persist.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 300
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 700

排除标准

  • 1. Females of childbearing potential (unless a negative HCG test can rule out pregnancy within the inclusion window)
  • 2. Known bleeding diathesis (medically induced coagulopathy (e.g. warfarin, NOAC, clopidogrel) does not exclude the patient)
  • 3. Suspected or confirmed acute intracranial bleeding
  • 4. Suspected or confirmed acute stroke
  • 5. Unwitnessed asystole
  • 6. Known limitations in therapy and Do Not Resuscitate-order
  • 7. Known disease making 180 days survival unlikely
  • 8. Known pre-arrest CPC 3 or 4 functional status
  • 9. >3 hours (180 minutes) from ROSC to screening
  • 10. Systolic blood pressure <80 mm Hg despite fluid loading/vasopressor and/or inotropic medication#
  • 11. Use of intra-aortic balloon pump/axial flow device/ECMO†
  • 12. Temperature on admission <30°C
  • Further exclusion criteria specific to the trial interventions:
  • 13. Known allergy from dexamethasone or olanzapine
  • 14. Ongoing (within 48 h) treatment with dexamethasone or olanzapine
  • 15. Known back or hip condition that precluded the patients from being positioned with backrest from 0 to 45-degree angle
  • 16. Known or suspected Long QT Syndrome (LQTS)
  • 17. Known active fungal disease. Localized skin lesions do not exclude patients from inclusion
  • 18. Estimated body weight <45kg
  • # If the systolic blood pressure (SBP) is recovering during the inclusion window (180 minutes) the patient may be included
  • † If the patient is weaned and the device is removed during the inclusion window (180 minutes) the patient may be included

研究者

发起方
Department of Cardiology, Copenhagen University Hospital, Rigshospitalet

相似试验